Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Pharmaceutics|February 24, 2024
An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus ReactivityDongHoon Yu, Sabrina Wagner, Martin Schütz, et al.Cell Death & Disease|May 27, 2026
Inhibition of RNA polymerase II-activating CDK9 and CDK12/13, but not of cell cycle relevant CDKs, induces apoptosis by downregulating the short-lived Bcl-2 proteins Mcl1 and Bfl1/A1Karina S Krings, Judith Hatzfeld, Sandra Weller, et al.Journal of Medicinal Chemistry|October 25, 2019
Kinase Chemodiversity from the Arctic: The BreitfussinsKine Ø Hansen, Jeanette H Andersen, Annette Bayer, et al.Angewandte Chemie (International Ed. in English)|August 28, 2019
Discovery of the Hedgehog Pathway Inhibitor Pipinib that Targets PI4KIIIßLea Kremer, Elisabeth Hennes, Alexandra Brause, et al.Nature|February 21, 2014
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cellsMagdalena Paolino, Axel Choidas, Stephanie Wallner, et al.Chemmedchem|September 30, 2017
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of CancerUlrich Lücking, Arne Scholz, Philip Lienau, et al.Stem Cell Reports|February 19, 2019
Dual Inhibition of GSK3β and CDK5 Protects the Cytoskeleton of Neurons from Neuroinflammatory-Mediated Degeneration In Vitro and In VivoLydia Reinhardt, Susanne Kordes, Peter Reinhardt, et al.Cell Reports|September 21, 2017
Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline CarcinomaJohannes Brägelmann, Marcel A Dammert, Felix Dietlein, et al.Pageof 4